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Abstract
Background: Whilst people with intellectual disability grow older, evidence has emerged internationally about the
largely unmet health needs of this specific ageing population. Health checks have been implemented in some
countries to address those health inequalities. Evaluations have focused on measuring process outcomes due to
challenges measuring quality of life outcomes. In addition, the cost-effectiveness is currently unknown. As part of a
national guideline for this population we sought to explore the likely cost-effectiveness of annual health checks in
England.
Methods: Decision-analytical Markov modelling was used to estimate the cost-effectiveness of a strategy, in which
health checks were provided for older people with intellectual disability, when compared with standard care. The
approach we took was explorative. Individual models were developed for a selected range of health conditions,
which had an expected high economic impact and for which sufficient evidence was available for the modelling. In
each of the models, hypothetical cohorts were followed from 40 yrs. of age until death. The outcome measure was
cost per quality-adjusted life-year (QALY) gained. Incremental cost-effectiveness ratios (ICER) were calculated. Costs
were assessed from a health provider perspective and expressed in 2016 GBP. Costs and QALYs were discounted at
3.5%. We carried out probabilistic sensitivity analysis. Data from published studies as well as expert opinion
informed parameters.
Results: Health checks led to a mean QALY gain of 0.074 (95% CI 0.072 to 0.119); and mean incremental costs of
£4787 (CI 95% 4773 to 5017). For a threshold of £30,000 per QALY, health checks were not cost-effective (mean
ICER £85,632; 95% CI 82,762 to 131,944). Costs of intervention needed to reduce from £258 to under £100 per year
in order for health checks to be cost-effective.
Conclusion: Whilst findings need to be considered with caution as the model was exploratory in that it was based
on assumptions to overcome evidence gaps, they suggest that the way health systems deliver care for vulnerable
populations might need to be re-examined. The work was carried out as part of a national guideline and informed
recommendations about system changes to achieve more equal health care provisions.
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Background
Older people with intellectual disability (ID) have more
health conditions than people of a similar age in the
general population, but many of these go undetected
and untreated [1]. The higher morbidity has been ex-
plained by a combination of genetic and lifestyle factors,
as well broader social determinants of health, which
means that people are much more likely to experience
pervasive disadvantage [1–4]; this includes active dis-
crimination and other barriers people with ID face when
accessing standard health services [5]. Whilst those fac-
tors play a role for all people with ID independently of
their age, they accumulate over a person’s lifetime and
have a greater impact on quality of life as people age [5–
9]. Health conditions typically associated with ageing in
the general population often occur at a much earlier age,
with higher prevalence and in combination [9–14].
There are substantial challenges of identifying health
conditions early in this population due to ‘diagnostic
overshadowing’, i.e. where physical and mental health
symptoms are not only misattributed to the ID but also
to age-related changes [5, 15]. The consequences are de-
layed diagnosis and treatment [5, 7, 15–17]. As a result,
their life expectancy at birth – although increasing – is
20 years lower than for people without ID [18–20].
Health checks for people with ID have been intro-
duced in countries such as the United Kingdom, Canada
and Australia to improve detection, treatment and pre-
vention of new health conditions in this population [21,
22]. In England, health checks were introduced in 2008
in the form of a national scheme which incentivises gen-
eral practices to offer checks to people registered as hav-
ing an ID each year (which is why they are typically
referred to as ‘annual health checks’) [23]. Staff from
practices which opt into the scheme are required to
undergo specialist training. This includes the use of tem-
plates such as the Cardiff Health Check, and more re-
cently the National Electronic Health Check; the latter
incorporates a wide range of questions about health con-
ditions including ageing-related disorders, bowel and
breast cancer screening and tests for osteoporosis. It also
includes a section on mental health [24].
Evaluations of the national scheme found that annual
health checks (AHCs) led to the identification of unmet
health needs and unrecognised life-threatening condi-
tions [21, 23]. However, those ‘effectiveness’ evaluations
have focused on short-term process measures, such as
the number of health checks attended, health assess-
ments and investigations done and common health con-
ditions diagnosed. One would expect that AHCs have an
impact on health-related quality as well as on quantity
of life because health conditions are identified and
treated earlier on, or sometimes even prevented. How-
ever, robust evidence in this regard is still lacking. In
addition, there is a gap in knowledge about the
cost-effectiveness of AHCs [23].
The aim of this explorative economic study was to es-
timate impacts on long-term quality and quantity of life
and costs of the AHC scheme for older people with ID
in England. The work was carried out to inform a na-
tional guideline on this topic for the National Institute
for Health and Care Excellence [25].
Methods
Procedure
We carried out an explorative cost-utility analysis com-
paring a strategy in which older people with ID were of-
fered health checks every year in general practice
(primary care) versus a strategy in which they received
standard primary care. The first referred to care pro-
vided in general practices as part of the AHC scheme,
whilst standard care referred to care provided by general
practices not part of such scheme. We hypothesized that
earlier identification of health conditions due to regular
check-ups would lead to health improvements as well as
potential reductions in costs due to fewer treatments for
health conditions at a more severe stage. The analysis
was explorative in nature and it was not the aim of the
analysis to include all possible economic consequences
of AHCs. Instead, the model focused on those health
conditions that were covered by current checklists used
in primary care and most important in terms of their
(expected) economic impact. Decision-analytical Markov
models were constructed to estimate lifetime
quality-adjusted life years (QALYs) and costs from a Na-
tional Health Service (NHS) perspective in 2016 prices,
discounted at a standard annual rate of 3·5% [26]. For
each of a selected range of health conditions a separate
Markov model was developed, generating the present
values of lifetime cost and QALY gain linked to earlier
identification or treatment of this particular health con-
dition. We then aggregated the results of all single
models in terms of their present values of lifetime costs
and QALY gains. Double counting of overlapping health
conditions was avoided by adjusting prevalence rates, or
by only including those conditions that were expected to
occur first. The net present value of the costs of yearly
health checks was then added to those aggregated costs
to derive a final incremental cost-effectiveness ratio
(ICER). The modelling considered a hypothetical popula-
tion aged 40 years (although for some health conditions
older starting ages were applied), who were followed
until death. The models were constructed using Micro-
soft Excel and applied half cycle corrections, probabilis-
tic sensitivity analysis and Monte Carlo simulation to
assess the impact of changes in parameters on the ICER.
The method is explained by describing the general ap-
proach that was applied across all models; where there
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was a deviation from this approach (for a particular
health condition), this is highlighted. A technical report
is available on NICE’s website, which describes each sin-
gle model for each health condition [27].
Sources from which data were taken to inform the
modelling are referred to and described under respective
sub sections. Data referred to population or clinical sam-
ples. For example, a large Irish cohort study was the pri-
mary source for probabilities that people developed
health conditions. Probabilities for the identification of
health conditions stemmed from data from a large pri-
mary care database in England. We used data from clin-
ical studies to model the likely consequences of an
earlier versus later identification of health conditions.
Details of how the literature was searched for this study
are provided in Additional file 1.
Figure 1 illustrates the key health states in our models
and possible transitions between them during each cycle.
Each year a person could develop a health condition, be
identified with a health condition (or not), get treatment
(or not), survive, or die (either because of the health
condition or because of other causes). Of those people
alive, they could live throughout each yearly cycle with
or without a health condition, which was either treated
or not. For some health conditions (high blood pressure,
diabetes), a distinction was made whether a person’s
health condition was managed well (due to regular
check-ups provided during AHCs) or just treated nor-
mally. Whether a person was identified with a health
condition and received treatment for it (or whether the
health condition was managed more closely rather than
just treated normally) could influence the disease pro-
gression and yearly probability of death from the condi-
tion (if indicated by evidence). A quality of life weight
(in the form of health utilities) and a cost were assigned
to each event state (with death set equal to zero). We
ran the models and calculated total costs and QALYs
based on the time each person spent in each health
state.
Health conditions: selection, incidence and progression
A selected number of ageing-relevant health conditions
were included in our modelling: osteoporosis; breast
cancer; bowel cancer; cataract; glaucoma; hearing prob-
lems; diabetes; hypertension. Coronary heart disease
(CHD) and stroke were modeled as consequences of dia-
betes or hypertension; hip fracture was modeled as a
consequence of osteoporosis. Not included due to a lack
of economic evidence or because of expected low eco-
nomic impact were: cervical cancer screening (smear
test); prostate cancer; lung cancer; body mass index,
cholesterol, weight; thyroid problems; arthritis; chronic
obstructive pulmonary disease (COPD) and asthma; epi-
lepsy; immunization status; mental health and dementia.
The rationale for why health conditions were included
or excluded is presented in Table 1 (and a more detailed
explanation is provided in Additional file 1: Table S1).
Each health condition was modelled separately. For
conditions known to interact with each other substan-
tially (diabetes and hypertension), incidence rates were
adjusted to avoid double-counting of costs and out-
comes. For the same reason, conditions (such as heart
diseases, stroke or hip fracture) typically preceded by
conditions already covered in the modelling (hyperten-
sion, diabetes or osteoporosis in these cases) were not
modelled separately. The model focused on the new oc-
currence (incidence) of conditions and did not consider
conditions that existed before the person reached the
age of 40 years (or respective starting ages). Data on the
yearly incidence and progression of conditions were
Fig. 1 Markov modelling, simplified transition-state-diagram (HC=Health condition)
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Table 1 Rational for including or excluding health conditions
Health condition Included/
excluded
Rationale
Arthritis Excluded Despite a high prevalence, the expected impact on costs and outcomes was likely to be low or medium
due to uncertainties around optimal identification and management; in addition there was no
consistent evidence of whether AHC would improve the identification or management of arthritis.
High blood pressure
(hypertension)
Included The expected impact on costs and outcomes was high; robust (cost-) effectiveness evidence for blood
pressure management was available; evidence was also available that showed that AHC led to
improved identification and management of high blood pressure.
Body mass index, weight,
cholesterol
Excluded Overall, there was only limited evidence that AHC was able to influence those health promotion
outcomes.
Bowel cancer screening Included The expected impact on costs and outcomes was high because of a high prevalence of the condition,
the availability of a national screening programme, and the availability of (cost-) effective treatment; although
uptake has not been considered in the evaluations of AHCs there is evidence that additional information
provided by general practitioners increases uptake.
Breast cancer
(screening via mammogram)
Included The expected impact on costs and outcomes was high because of the high prevalence of the
condition, the availability of a national screening programme, and of cost-effective treatment; although
uptake has not been considered in the evaluations of AHCs there is evidence that additional information
provided by general practitioners increases uptake.
Cataract Included The expected impact on costs and outcomes was high because of the high prevalence, availability of
(cost-) effective treatment, and strong evidence that AHCs led to an increase in eye tests.
Cervical cancer screening Excluded The expected impact on costs and outcomes was low because of the low prevalence in this
population.
COPD and asthma Excluded Evidence was insufficient: the prevalence of asthma was not well established for this population; there
was no evidence that AHC would lead to changes in the identification or management of COPD or
asthma.
Dementia Excluded Evidence was insufficient; in particular it was not clear whether dementia was currently checked in AHCs, and
whether AHCs led to better identification.
Epilepsy Excluded Evidence was insufficient; in particular there was not enough robust evidence of cost-effective
treatment.
Heart disease Included
(indirectly)
Heart disease was modelled as a consequence of hypertension and diabetes, which were strong
predictors of heart disease. Heart disease was not modelled separately to avoid double of counting
economic consequences.
Hearing impairment Included The expected impact on costs and outcomes was high due to the high prevalence and high impact
for this population. There was robust evidence that AHC led to an increase in hearing tests; (cost-)
effective treatment was available.
Glaucoma Included The expected impact on costs and outcomes was high; the impairment linked to glaucoma was and
there was strong evidence that AHC led to more eye tests being carried out; (cost-) effective
treatment was available.
Hip fracture Included
(indirectly)
This was modelled as a consequence of osteoporosis, which was a strong predictor fracture. Hip
fracture was not modelled separately to avoid double counting of economic consequences.
Immunisation status Excluded The expected impact on costs and outcomes was low; checking for immunisation status is part of
another incentivised scheme in primary care. This suggested a more limited role of AHCs in further
improving uptake.
Lung cancer/ smoking Excluded The expected impact on costs and outcomes was low due to lack of evidence of cost-effective treat
ment options that would be influenced by an earlier identification; also lack of robust evidence
whether identification improved through AHC.
Mental health Excluded Evidence was insufficient; whilst prevalence data were available, there was no evidence about whether
AHC led to a better identification of mental health problems; there was also a lack of evidence
regarding (cost-) effective treatment options for this population.
Osteoporosis (screening) Included The expected impact on costs and outcomes was high due the high prevalence and the availability of
screening tools that led to an increase in the identification of osteoporosis and reduction in (costly)
fractures. Screening for osteoporosis is covered by the new AHC tool in England.
Prostate cancer Excluded Evidence was insufficient; prevalence data were not available and there was no robust evidence about
(cost-) effective treatment options and whether AHCs led to increase in identification or improved
management of the condition.
Stroke Included
(indirectly)
This was modelled as a consequence of hypertension and diabetes, which were strong predictors of
stroke. Stroke was not modelled separately to avoid double counting economic consequences.
Thyroid problems Excluded There is an overall lack of evidence suggesting that expected impact of identification or monitoring through
annual health checks is likely to have a large impact on costs or health outcomes.
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derived from the Intellectual Disabilities Supplement to
the Irish Longitudinal Study on Aging (IDS-TILDA)
[17], with the exception of hearing problems, for which
data were taken from two other sources because they
were not available from IDS-TILDA [28, 29]. Parame-
ters, their values, sources and descriptions are shown in
Table 2.
Populations: starting ages, gender and mortality
Generally, a starting age of the cohorts of 40 years was
used because this was consistent with that used by
IDS-TILDA (and was considered appropriate by our ex-
perts due to the earlier onset of age-related conditions).
However, for certain health conditions for which AHCs
led to changes in screening uptake (breast and bowel
cancer) or for which incidence rates increased strongly
at a later age (osteoporosis), different starting ages were
used according to the age from when screening was of-
fered (or from which prevalence strongly increased)
(Table 2). We calculated yearly age-specific transition
probabilities from alive to dead using the National Life
Tables for England [30]. Adjustments were made reflect-
ing the three times higher mortality rate for people with
ID [6]. For health conditions which could end in death
(breast cancer, bowel cancer, diabetes, hypertension),
additional calculations were carried out to derive yearly
probabilities of death from those causes using national
data sources [31–34].
Uncertainty
The impact of uncertainty around parameter values on
the ICER was examined using probabilistic sensitivity
analysis (PSA). In PSA, the full value range rather than a
single value is considered for each parameter. This was
done by determining the distributions that a value could
take for each parameter and then running a large num-
ber (1000) of Monte Carlo simulations, which produced
the results of different combinations of random draws.
The choice of distributions followed the approach sug-
gested by Sculpher [35]. In addition, one-way sensitivity
analysis was applied for values that were particularly
uncertain.
Costs of the scheme
The costs of health checks were estimated in consult-
ation with experts from the Committee. They were
asked to estimate the resource inputs required for deliv-
ering AHC according to best practice. Unit costs were
then attached from national sources [36]. The relevant
parameters, values, sources and details are shown in
Table 3. Based on yearly costs we calculated the present
value of total costs over a person’s lifetime starting from
40 years of age.
Cost consequences
Unit costs were attached to the different states. This in-
cluded the cost of participating in (additional) screening
tests and other procedures for the diagnosis of health
conditions or (immediate) follow-on treatment; in the
case of breast cancer this included the cost of
over-diagnosis due to additional screening procedures.
Costs also included those for yearly treatment. Data for
the unit cost of procedures or tests and cost for treating
conditions were taken from recent national sources or
economic evaluations [31, 40–49, 36–39]. In some in-
stances [38, 41], cost estimates referred to present values
of differences in life-time costs - in which case we dir-
ectly assigned those cost differences to the additional
risk that someone would be identified with the health
condition (breast cancer) or would get monitored annu-
ally in the AHC group (diabetes). Parameters, value,
sources and details are shown in Table 3.
Effectiveness
Effectiveness of AHCs referred to increased access to
standard treatment as a result of changes in identifica-
tion of health conditions or – in the case of diabetes and
hypertension - to better management of those conditions
due to regular check-ups. Thus, in each of the models,
people in the AHC and standard care groups had differ-
ent probabilities that their health conditions would be
identified, or that their condition would be well managed
(people receiving AHCs had a greater probability). For
the two cancers covered in the modelling (bowel and
breast cancers), this included data on increased screen-
ing uptake due to reminders provided during AHCs.
Earlier identification and increased access to treatment
(or better management of health conditions) were mod-
elled reflecting – where indicated by evidence – lower
probabilities of disease progression, progression into
more severe disease, and of death.
Data on uptakes of AHC, identification rates for health
conditions and better management of health conditions
were taken from a large national evaluation [23], as well
as from international evaluations of AHCs [50, 51], and
from expert views. Data on access to treatments (includ-
ing adherence to treatment) for those identified with a
health condition were taken from national statistics and
economic evaluations [31, 51–63]. Parameters, their
values, sources and descriptions are shown in Table 4.
Quality of life weights
Quality of life weights (utilities) were attached to health
states, which included different progression states for
some conditions. Data on health utilities were taken from
national (economic) evaluations and referred to the gen-
eral population in England [37, 38, 41, 44–47, 62–66]. For
some health conditions (diabetes and cataract), present
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values of differences in QALY gains (or losses) linked to
early identification or closer monitoring were already
available in aggregated form from economic modelling
studies, which included disease progression as relevant for
the condition [41, 47]. For hearing impairment, only in-
cremental values of health utility gain linked to ear-wax
removal (a common problem in this population) and to
hearing aid were available [61], and we thus assigned those
to additional probabilities for people to benefit from AHC.
Quality of life parameters, their values, sources and de-
scriptions are shown in Table 5.
Results
Findings of the base case analysis are shown as averages
per person (Table 6). AHCs led to a mean QALY gain of
Table 2 Parameter values (deterministic, in ranges) for
modelling: Yearly probabilities for developing health conditions,
and cohort starting ages
Data Source and details
Yearly probabilities for developing health conditions
Hypertension, diabetes excluded
40 to 49 years 0·35 to
1·14%
Derived from 3 years incidence data
from IDS-TILDA by McCarron and col-
leagues [17]
50 to 64 years 1·56 to
2·28%
As above
65 years+ 2·39 to
4·76%
As above
Stroke
40 to 49 years 0 to
1·11%
As above
50 to 64 years 0·23 to
1·13%
As above
65 years+ 0·44 to
2·85%
As above
Coronary heart disease (CHD)
40 to 49 years 0 As above
50 to 64 years 0·07 to
0·91%
As above
65 years+ 0·44 to
2·82%
As above
Diabetes
40 to 49 years 0 to
1·11%
As above
50 to 64 years 0·03 to
1·32%
As above
65 years + 0·07 to
1·83%
As above
Obesity
Proportion with
obesity (all ages)
33·5% As above
Bowel cancer
50 to 64 years 0·24 to
1.28%
Derived from 3 years incidence data for
all types of cancer from IDS-TILDA by
McCarron and colleagues [17] applied to
proportion of bowel cancer among all
types of cancer from Cancer Research
UK [30]
65 years+ 0·3 to
2·49%
As above
Breast cancer
50 to 64 years 0 to
0·16%
Derived from 3 years incidence data for
all types of cancer from IDS-TILDA by
McCarron and colleagues [17] applied to
proportion of breast cancer among all
types of cancer from Cancer Research
UK [30]
65 years + 0·04 to
0·19%
As above
Osteoporosis
Table 2 Parameter values (deterministic, in ranges) for
modelling: Yearly probabilities for developing health conditions,
and cohort starting ages (Continued)
Data Source and details
50 to 64 years 2·8 to
5·9%
Derived from 3 years incidence data
from IDS-TILDA by McCarron and col-
leagues [17]
65 years + 4·8 to
11·2%
As above
HIP fracture
50 to 64 years 0·07 to
0.55%
As above
65 years + 0·08 to
1·11%
As above
Cataract
40 to 49 years 0·9 to
3%
As above
50 to 64 years 1·32 to
3·2%
As above
65 years + 1·04 to
4·09%
As above
Glaucoma
40 to 49 years 0 to
1.2%
As above
50 to 64 years 0·14 to
1·1%
As above
65 years + 0 to
0·15%
As above
Hearing problems
All ages 2 to
13·4%
Carvill [28] and Kerr and colleagues [29]
Cohort starting ages (if different from 40 years), years
Bowel cancer 60 Starting age of national screening
programme
Breast cancer 50 As above
Osteoporosis 50 Age when prevalence strongly increases
according to data from IDS-TILDA by
McCarron and colleagues [17]
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Table 3 Parameter values (deterministic, in ranges) for modelling: Cost inputs
Data Source and details
Cost inputs for annual health checks
General practice doctor £72 PSSRU [36]; refers to 20 min of general practice doctor time with unit cost per hour of face-to-
face time of £216 (includes all administrative, preparation and follow-up costs, cost of home
visits)
General practice nurse £43 PSSRU [36]; refers to 1 h of general practice nurse time with unit cost per hour of £43
Support worker £136 Expert view; refers to 8 h of support worker time with unit cost per hour of face-to-face time
of £17
Social worker £7 PSSRU [36]; refers to 5 min of social worker time with unit cost per hour of client-related time
of £79
Cost inputs for modelling hypertension
Diagnosis £29 to £89 Lovibond and colleagues [37]
Hypertension management £34 to £102 As above
Treating stroke (initially) £5633 to
£16,901
As above
Subsequent treatment of stroke £619 to
£1856
As above
Treating coronary heart disease
(initially)
£1854 to
£5561
As above; includes costs of heart failure (£2929), angina (£3273), heart attack =myocardial
infarction, MI (£5455); weighted by their prevalence proportions from IDS-TILA by McCarron
and colleagues [17] in relation to all coronary heart disease conditions: heart failure (51%), an-
gina (21%), MI (28%)
Subsequent treatment of coronary
heart disease
£143 to
£428
As above; includes costs of heart failure (£311), angina (£187), heart attack =myocardial
infarction, MI (£312); weighted by their prevalence proportions from IDS-TILA by McCarron
and colleagues [17] in relation to all coronary heart disease conditions: heart failure (51%), an-
gina (21%), MI (28%)
Cost inputs for modelling diabetes
Δ Controlled vs. uncontrolled
glucose, non-overweight patients
-£618 to
£2877
Clarke and colleagues [38]; refers to present of total lifetimes costs; for non-overweight pa-
tients treated with insulin
Δ Controlled vs. uncontrolled
glucose, overweight patients
-£5486 to
£2875
As above; refers to present of total lifetimes costs; for overweight patients treated with
metformin
Cost inputs for modelling bowel cancer (screening)
FOBT tests £16 to £19 Tappenden and colleagues [39]; refers to 2 FOBT tests (in case first is not returned)
Colonoscopy £469 to
£573
National Schedule for Reference Costs 2015–16; refers to diagnostic colonoscopy [40]
Removing adenoma £122 to
£149
As above
Admittance for bleeding £712 to
£870
As above
Bowel cancer treatment detected
through screening
£5971 to
£7298
Cancer Research UK [30]
Bowel cancer treatment clinically
detected
£7782 to
£9511
As above
Cost inputs for modelling breast cancer (screening)
Mammogram per woman invited for
screening
£14 to £36 Pharoa and colleagues [31]
Treating over-diagnosis £2047 to
£2501
As above
Δ Treatment, early vs. late stage
cancer, under 65 years (lifetime)
-£11,739 to
-£14,347
Laudicella and colleagues [41]
Δ Treatment, early vs. late stage
cancer, over 65 years (lifetime)
-£6404 to
-£7827
As above
Cost inputs for modelling osteoporosis
DAX scan and General Practitioner
(GP) consultation
£113 to
£137
NICE [41, 43]
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0.074. The 95% Confidence interval (CI) ranged from
0.072 to 0.119. Mean incremental costs were £4787 with
a CI 95% of 4773 to 5017. The mean ICER was £85,632
(95% CI 82,762 to 131,944). The yearly cost of an AHC
was £258 per person. For health service decision-makers
in England an ICER of less than £20,000 (or in some cir-
cumstances less than £30,000) is assumed to indicate the
cost-effectiveness of an intervention [42]. Thus, AHC
could not be considered cost-effective.
Another way of presenting our findings, including the
uncertainty surrounding them, is through a
cost-effectiveness plane (Fig. 2). The graph shows the in-
cremental effects (measured in QALYs) on the x-axis
and incremental costs on the y-axis. The dots represent
the results of 1000 Monte Carlo simulations. As can be
seen, only a few dots lie below the lines that represent
the cost per QALY threshold for cost-effectiveness at
£20,000. At a more generous threshold of £30,000 per
QALY (which used to be and is still considered some-
times the upper range of a cost per QALY threshold), a
few more dots lie under the line. However, the vast ma-
jority of dots are centred at incremental costs of £5000
and incremental QALY gains of less than 0.1, suggesting
ICERs of above £50,000 and higher.
Findings from additional one-way sensitivity analysis
showed that the cost of an AHC was the only parameter
that substantially influenced the results and could turn
the decision whether AHCs were cost-effective from a
negative to a positive one. Findings in Table 7 show that
if AHC could be provided at £50 per person per year
then the probability of cost-effectiveness would be 70.1%
(88.6%) at a cost per QALY threshold of £20,000
(£30,000); if the costs of annual health checks were £75
per person per year the probability would be 37.1%
(66.1%); and at a cost of £100 per person per year they
would no longer be cost-effective (that is, their probabil-
ity of being cost-effective was less than 50%).
Discussion
The aim of our study was to explore the likely
cost-effectiveness of a strategy, in which AHC are incen-
tivised for people with ID as they age versus a strategy
in which standard care is provided. Modelling was used
to address large evidence gaps in this area. This included
Table 3 Parameter values (deterministic, in ranges) for modelling: Cost inputs (Continued)
Anti-osteoporotic medication (per
year)
£54 to £334 NICE [41, 43]; refers to the most commonly prescribed drugs: alendronate, etidronate
risedrinate, raloxifene and strontium ranelate; and recommended doses
Treating hip replacement (HIP)
fracture, 1st year
£14,481 to
£14,800
Leal and colleagues [44]
Treating HIP fracture, 2nd year £2160 to
£2272
As above
Cost inputs for modelling cataract
Initial optometrist test £21 DH [45]
Optometrist diagnosis test £92 to £472 Burr and colleagues [46]
Cataract surgery (lifetime) £1218 to
£9211
Frampton and colleagues [47]
Cost inputs for modelling glaucoma
Initial optometrist test £21 DH [45]
Optometrist diagnosis test £92 to £472 Burr and colleagues [46]
Treating mild glaucoma (per year) £259 to
£777
As above
Treating moderate glaucoma (per
year)
£325 to
£875
As above
Treating severe glaucoma (per year) £232 to
£695
As above
Treating visual impairment (per year) £721 to
£927
As above
Cost inputs for modelling hearing problems
Ear wax removal £36 to £44 Clegg and colleagues [48]; refers to primary care
Hearing specialist assessment £46 to £68 NHS National Tariff 2017 to 2019 [49]
Hearing aid assessment £48 to £58 As above
Hearing aid, initial £268 to
£370
As above
Hearing aid, follow on care £23 to £28 As above
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Table 4 Parameter values (deterministic, in ranges) for modelling: Inputs for effectiveness (including data on identification, screening
uptake, progression, further investigation and treatment)
Data Source and details
Effectiveness of annual health checks in terms of: identification; uptake of national screening; management of conditions (in probabilities, annual
health check vs. standard care group)
Hypertension identified and managed 85 to 95·3% vs.
71·4 to 87·8%
Buszewicz and colleagues [23]
Participation in bowel cancer screening (FOBT), difference
between AHC and standard care, in percentage points
4·1 to 7·8% Hewitson and colleagues [52] and expert views
Participation in breast cancer screening (mammogram) 54·3 to 59·3% vs.
47 to 52%
Derived from IDS-TILDA by McCarron and colleagues [17],
Gardner and colleagues [53] and expert views
Diabetes managed (identification found similar in both
groups)
69·9% (SD 34·2) vs.
56.8% (SD 29·4)
Cooper and colleagues [16]; refers to proportion of people
whose health monitoring needs are met
Osteoporosis investigated 85 to 95% vs. 66·2
to 86·8%
Derived from Lennox and colleagues [49] and expert views
Person with eye problem (cataract or glaucoma) is referred to
eye exam
90% vs. 58.9% (SD
0·24)
Derived from Buszewicz and colleagues [23] and expert views
Person with hearing problems is referred to hearing
assessment
90% vs. 27·6 to
33%
As above
Effectiveness of: identification; uptake of national screening; management of conditions
Relative Risk (RR) in stroke, CHD and death, managed versus unmanaged hypertension
Stroke
40 to 59 years 0·61 to 0·65 Moran and colleagues [52]
60 years + 0·66 to 0·71 As above
CHD
40 to 59 years 0·72 to 0·74 As above
60 years + 0·74 to 0·78 As above
Death
40 to 59 years+ 0·83 to 0·89 As above
60 years + 0·91 to 0·92 As above
Increased risk of stroke in people with hypertension 3 to 5 Straus and colleagues [55]
Increased risk of CHD in people with hypertension 2 to 3 Padwal and colleagues [54]
Absolute risk reductions (in percentage points) in death for
people participating in bowel screening
1·01% Scholefield and colleagues [57]
Progression probabilities for glaucoma, treatment vs. not in treatment
Progression from mild to moderate 22% vs. 25% Burr and colleagues [44]
Progression from moderate to severe 7% vs. 11% As above
Progression from severe to visual impairment 6% vs. 10% As above
Relative risk reduction of death from breast cancer for women
invited for mammography
0·73 to 0·89 Pharoah and colleagues [31]
Probabilities for further investigations and treatment (after screening or diagnosis)
Hypertension
Adherence to management 75% (in one-way
SA: 50%)
Moran and colleagues [54]
Bowel cancer
Screening positive and requiring further investigation 1·84 to 2·1% Raine and colleagues [58]
Visit at specialist clinic for further investigation if screening
was positive
74·7 to 91·3% Logan and colleagues [59]
Bowel cancer if screening was positive 9·09 to 11·11% As above
Pre-cancer polyps if screening was positive 24·48 to 29·92% As above
Admission for bleeding due to further investigation 0·39 to 0·48% Tappenden and colleagues [37]
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utilising a wide range of data sets and consulting experts
on parameters and values that informed the model.
Findings from our study suggest that AHCs provided to
older people with ID are unlikely to be cost-effective
from a health service perspective. This conclusion was
robust across many scenarios; the only scenario in which
AHCs were cost-effective was when their annual cost
was reduced to about one-third of their current cost (a
figure estimated by experts in the field).
One strength of this study was that the potential
cost-effectiveness of AHCs was examined using appro-
priate methods to take account of uncertainties [67].
Second, experts were consulted on the model structure,
inclusion of health conditions and parameters that were
uncertain. Third, conservative assumptions were made
to reflect the realities of current practice in England. For
example, the cost of an AHC included not only cost in-
curred by general practice but also the cost of additional
support provided by support workers, which help people
to: attend medical appointments; understand the nature
and reasons of visits and tests and test results. Whilst
not everyone will need this kind of support and support
workers will be employed independently of whether they
provide help with AHCs, it is a relevant opportunity cost
since support workers’ time could be otherwise spent on
helping the individual with something else or helping
another person. Fourth, the analysis was informed by
data from two recent, large-scale studies on this topic,
helping to fill some evidence gaps (namely incidence of
health conditions for this population [17] and on effect-
iveness of AHCs at the national level [23]).
This exploratory study has limitations linked to the
many gaps in evidence, including those of: health utility
values; incidence rates for some health conditions; ac-
cess rates to secondary care treatment; and unit costs.
Values for those parameters were taken from studies
that referred to the general population; it is possible
that they are different for people with ID. For example,
there is currently not much knowledge about the valid-
ity of generic health-related quality of life measures
such as the EQ-5D for this population, which is the
measure used to derive health utilities [68, 69]. Whilst
the experts we consulted thought that health utilities
for this population were lower than in the general
population due to the pervasive disadvantage and dis-
crimination they experienced, no evidence could be
identified to inform such values. However, this is un-
likely to have influenced our incremental or net find-
ings substantially since utilities would apply to all
health states and would not change incremental
QALYs, which are calculated in relative terms. A num-
ber of important health conditions could not be in-
cluded in the modelling either because their incidence
was not known from IDS-TILDA (e.g. asthma, chronic
Table 4 Parameter values (deterministic, in ranges) for modelling: Inputs for effectiveness (including data on identification, screening
uptake, progression, further investigation and treatment) (Continued)
Data Source and details
Osteoporosis
Prescription of drugs to person identified with osteoporosis 99·6% Presentation by Shepstone at National Osteoporosis
Conference 2016; [58] refers to findings from SCOOP study
Cataract
Corrected with glasses if referred to eye exam 50 to 67% Lennox and colleagues [51]
Surgery if referred to eye exam 5 to 9% Expert view
Glaucoma
Adherence to treatment 63·9 to 78·1% Okeke and colleagues [61]; mean of 71%, value range +/−
10%
Hearing problems
Hearing problem due to blocked ear wax (i.e. no referral
required)
15·7 to 50% Robertson and colleagues [20] and Clegg and colleagues [48]
Hearing problem not due to blocked ear wax and referral
made to specialist
50 to 84·7% Derived as residual from above
Person referred to specialist assessment attends it 80 to 90% Expert view
Person assessed by specialist as requiring hearing aid 42·2 to 51·6% Lennox and colleagues [50]
Person requiring hearing aid accepts and starts using it 36·8 to 86% Morris and colleauges [59]
Breast cancer
Breast cancer identified through mammogram 73·3 to 93·8% Sinclair and colleagues [63]
Relative risk of over-diagnosis for women invited to
mammography
1·19 As above
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obstructive pulmonary disease) or because there was a
lack of data on the costs and outcomes of earlier identi-
fication or treatment (e.g. thyroid problems, epilepsy,
arthritis). Especially for conditions like dementia and
mental illness, more evidence is needed about how
to best identify those conditions in this population and
about the (cost-) effectiveness of treatment and support
options. In addition, for the majority of health condi-
tions no evidence was available on follow-on treatments
in secondary care once health conditions have been
identified as a result of AHCs.
The impact of decent additional support in secondary
care on access is currently not known. This also includes
a lack of knowledge about the cost of this kind of add-
itional support. In addition to those limitations, we were
also unable to include a potential impact of earlier iden-
tification and treatment of health conditions on care
home admission. Decisions about whether a person with
ID is admitted to a care home are strongly influenced by
their deteriorating health [70]. However, a lack of data
prevented us from considering this potential economic
impact. Similarly, we were not able to consider the im-
pact on carers. This refers to the costs linked to the time
spent by carers for supporting the person with ID ahead
of, during and after medical appointments. This includes
their traveling time to get to health care facilities. This
cost is likely to present a large cost component of the
overall support for people with ID. Whether this cost is
influenced through the introduction of AHCs is cur-
rently not known, and presents an area where research
is needed.
Despite those limitations, our study is the first analysis
of long-term costs and outcomes of health checks for
people with ID. The need for economic evidence in this
area has been highlighted previously [10, 16, 23]. Previ-
ous studies which evaluated the cost-effectiveness of
AHCs have been small-scale, short-term or included
only a limited range of costs [16, 71, 72]. Findings from
those studies suggest that there might be some improve-
ments in overall health or reductions in service use but
those impacts did not reach significance. None of the
studies included the additional support from a support
or social worker in their costs of AHCs; as a result their
cost estimates for the intervention were substantially
lower than ours, and authors were more likely to con-
clude that health checks were likely to be cost-effective.
None of those studies looked at the population of older
people specifically. From the perspective of health ser-
vice expenditure alone, this is an important population
given the high rates of health and social care service util-
isation in old age [73].
As longevity improves for people with ID, it is
imperative to consider how to best support the
complex needs of this population in order to make
the most cost-effective use of resources. Our find-
ings highlight some of the dilemmas that commis-
sioners and strategic decision-makers face. For
example, changing only one part of the system
(here: the identification of health conditions in pri-
mary care) is not leading to health-related quality
Table 5 Parameter values (deterministic, in ranges) for
modelling: Quality of life weights (health utilities), Δ health
utilities and Δ QALYs
Data Source and details
Health utilities (including Δ) and QALYs
Stroke 0·31 to
0·94
Lovibond and colleagues [37]
Coronary heart disease 0·55 to
0·79
Derived from Lovibond and
colleagues [37] and Dyer and
colleagues [64]; weighted
average of health utility values
for heart failure (0.645), angina
(0.77) and MI (0.76); weighted
with their proportions of CHD
(as above)
Hypertension (without
cardiovascular event)
0·704 to
0·909
Lovibond and colleagues [37];
refers to general population
health utilities from Health
Survey England data
Bowel cancer 0·697
(+/−10%)
Whyte and colleagues [65]
Bowel cancer stages
Duke’s A, B, C,D
0·74; 0·70;
0·5; 0·25
(+/− 10%)
Tappenden and colleagues
[66]
Breast cancer 0·627 to
0·767
Whyte and colleagues [65]
HIP fracture, 1st year 0·64 to
0·77
Without HIP fracture, 50
to 60 years
0·6 to
0·85
As above
Without HIP fracture, 60
years +
0·55 to
0·82
As above
Glaucoma, mild 0·72 to
0·88
Burr and colleagues [46]
Glaucoma, moderate 0·67 to
0·82
As above
Glaucoma, severe 0·64 to
0·78
As above
Health utility gain (Δ)
from removed ear wax
0·0054 to
0·0066
Morris and colleagues [62]
Health utility gain (Δ)
from hearing aid
0·035 to
0·105
NICE [41]
QALYs (Δ), controlled vs.
uncontrolled diabetes in
non-overweight patients
−0·07 to
0·22
Clarke and colleagues [38];
refers to present value of
QALYs gained for intensive
vs. standard management
QALYs (Δ), controlled vs.
uncontrolled diabetes in
overweight patients
−0·04 to
0·48
As above
QALY gain linked to
cataract surgery
0·084 to
0·963
Frampton and colleagues [47]
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of life improvements or reductions in mortality if
people are not able to access and benefit from ef-
fective treatment options provided in other parts of
the system (in particular in secondary care). In
current practice, many hospitals fail to provide care
that is consistently accessible to people with ID
[74–77, 5]. Similarly, national screening pro-
grammes are not provided in a way that they are
accessible for people with ID [78–80]. The need for
collaborative approaches and wider system change
in order to reduce health inequalities for this popu-
lation has been highlighted in a number of studies
[77–82].
Our findings should also be considered in the context
of health checks provided to the general population of
older people. Health checks have now been introduced
in England for the general population aged 40 to 75
years. Concerns have been raised about their value for
money, and their ability to achieve more benefits than
harms has been questioned [83, 84]. Those concerns
stem from: gaps in evidence concerning effective inter-
ventions and best practice when test results are positive;
difficulties in explaining to patients the pros and cons of
intervening versus not intervening during early disease
stages; and the challenge of achieving behaviour change
within one or two visits. “Although the goal is improved
health outcomes, the pathway is long and tenuous, with
attrition at each point along the way” [83]. Many of
these challenges are likely to apply as much if not more
to older people with ID.
Legislation and guidance request that barriers for
people with ID in accessing health services are removed
and reasonable adjustments are made [85–87]. There-
fore, ethical considerations need to inform resource allo-
cation decisions alongside economic ones. In current
practice AHC offered to people with ID are a main pol-
icy vehicle for promoting a more equal access to health
services. Thus, removing them might be considered
highly unethical.
Seeking to respond to those challenges, the national
guideline of which this study was a part made a number
of recommendations about the provision of AHCs [25]:
In particular:
 AHCs should be followed by prompt referrals to
specialist services as needed; information on follow-
on actions should be recorded;
 Practitioners carrying out AHCs should inform
people about available health services including
national screening programmes;
The guideline also recommends further research into
the (cost-) effectiveness of alternative models and ap-
proaches for identifying health conditions and increasing
access to treatment. This includes the role of well man
and women clinics. In addition, the guideline makes a
Table 6 Base-case analysis results (probabilistic) – cost effectiveness annual health checks (AHC) vs. standard care, all prices in £
2015/16, per person
Incremental costs Incremental QALYs Incremental cost-effectiveness ratio (ICER)
Mean £4787.24 0·0743 £85,631.95
Standard deviation £230.05 0·0456 £46,312.30
95% Confidence interval £4772.98 to £5017.29 0·0715 to 0·119 £82,761.49.90 to £131,944.25
Fig. 2 Probabilistic sensitivity results presented as scatter plot (cost-effectiveness plane), all prices in £ 2015/16
Bauer et al. BMC Public Health          (2019) 19:706 Page 12 of 16
number of recommendations to improve accessibility of
health services beyond the provision of AHCs. It sets
out a system-wide responsibility to:
 Support people’s communication needs and
information preferences; this might include:
extending appointment times; contacting persons
before appointments; reminding people of
appointments; providing written information in an
accessible format; using visual aids when explaining
procedures or results; supporting the presence of an
advocate or someone the person trusts at
appointments;
 Increase peoples’ awareness of changing health
needs due to ageing; this might include
providing training for people and their family
members in recognising and managing ageing
related changes.
Furthermore, the guideline requests the introduction
of new roles to make those changes happen. This in-
cludes a single lead practitioner as point of contact in
each health care setting as well as champions in
health care teams who develop specific knowledge
and skills working with this population. Those recom-
mendations are - while important and desirable - also
ambitious in the current financial climate. The feasi-
bility of their implementation in practice remains to
be seen.
Conclusions
This explorative study is the first to estimate the
cost-effectiveness of health checks for people with intel-
lectual disability as they age. It is also the first economic
modelling study of health checks for people with intel-
lectual disability at any age. The findings from this study
suggest that the current focus by governments on pro-
viding yearly health checks for people with ID as they
age might not be good value for money. Findings from
this study informed recommendations in a guideline by
the National Institute for Health and Care Excellence in
England. Future research should investigate the impact
of AHCs and alternative models of identifying health
conditions on: the identification of health conditions
such as dementia and mental health disorders; access to
secondary care treatment and screening programmes;
health-related quality of life improvements; impact on
carers and support workers.
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